Search

Search Constraints

You searched for: Author/Creator Neimark, Ezequiel

Search Results

1. A Treat to Target Approach Decreases the Rate of CD‐Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn's Disease: Data From CALM2017 ACG Governors Award for Excellence in Clinical Research: 598. (October 2017)

2. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Issue 10 (18th September 2020)

3. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Issue 10 (27th February 2020)

4. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Issue 10114 (23rd December 2017)

7. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Issue 10340 (28th May 2022)

8. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Issue 10340 (28th May 2022)

9. S38 On-Body Injector Administration of Risankizumab for Treatment of Moderate-to-Severe Crohn's Disease: Data From the Fortify Open-Label Longitudinal Real-Life Handling Substudy. (December 2022)

10. S695 Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies. (October 2021)